Scandion Oncology (OM:SCOL BTA) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

SCOL BTA Stock Overview

A clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer.

About the company

SCOL BTA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 81.06% per year

Risk Analysis

Shares are highly illiquid

Makes less than USD$1m in revenue (DKK0)

Earnings are forecast to decline by an average of 43.4% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 2 more risks

Scandion Oncology A/S Competitors

Kancera

OM:KAN

SEK 239.0m

SenzaGen

OM:SENZA

SEK 225.7m

Cereno Scientific

OM:CRNO B

SEK 2.0b

Active Biotech

OM:ACTI

SEK 104.9m

Price History & Performance

Summary of all time highs, changes and price drops for Scandion Oncology
Historical stock prices
Current Share Price	SEK 5.62
52 Week High	SEK 8.76
52 Week Low	SEK 5.10
Beta	-0.24
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-22.16%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	SCOL BTA	SE Biotechs	SE Market
7D	2.6%	1.3%	1.9%
1Y	n/a	30.1%	24.3%

Return vs Industry: Insufficient data to determine how SCOL BTA performed against the Swedish Biotechs industry.

Return vs Market: Insufficient data to determine how SCOL BTA performed against the Swedish Market.

Price Volatility

Is SCOL BTA's price volatile compared to industry and market?
SCOL BTA volatility
SCOL BTA Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.1%
Market Average Movement	5.6%
10% most volatile stocks in SE Market	11.7%
10% least volatile stocks in SE Market	3.2%

Stable Share Price: SCOL BTA's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine SCOL BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	15	Bo Hansen	www.scandiononcology.com

Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company’s other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors.

Scandion Oncology A/S Fundamentals Summary

How do Scandion Oncology's earnings and revenue compare to its market cap?
SCOL BTA fundamental statistics
Market cap	SEK 240.17m
Earnings (TTM)	-SEK 77.71m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.1x

P/E Ratio

Is SCOL BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SCOL BTA income statement (TTM)
Revenue	DKK 0
Cost of Revenue	DKK 0
Gross Profit	DKK 0
Other Expenses	DKK 55.77m
Earnings	-DKK 55.77m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 25, 2022

Earnings per share (EPS)	-1.37
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did SCOL BTA perform over the long term?

See historical performance and comparison